Welcome to the board Angie You and Dan Puckett!
Excited to be working with Angie You and Dan Puckett again. Both have joined the board of directors at Candid Therapeutics https://lnkd.in/g8nhEdFN
Candid Therapeutics
生物技术研究
San Diego，CA 3,173 位关注者
Developing innovative therapeutics that can materially improve the lives of patients
关于我们
Clinical stage biotechnology company dedicated to advancing the treatment of a range of immunological conditions
- 网站
-
https://www.candidrx.com
Candid Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 私人持股
- 创立
- 2024
- 领域
- Biotechnology、Drug Development和Therapeutics
地点
-
主要
获取路线
US，CA，San Diego
Candid Therapeutics员工
动态
-
Thank you #NASDAQ for the recognition on Times Square
-
-
Thank you NYSE for recognizing our recent $370M private capital raise
-
-
Shortly after leading radiopharma startup RayzeBio to a $4B+ exit to Bristol Myers Squibb earlier this year, Ken Song hit the ground running for his next bet. He set up a shell company in the spring and went on a hunt for clinical-stage drugs. He looked at nearly 50 opportunities across pain, oncology and other disease areas before quickly settling on the potential of T cell engagers for autoimmune diseases. He assembled more than $370 million in funds for his new company, Candid Therapeutics, and acquired two biotech startups: Vignette Bio and TRC 2004. Both had inked licensing deals in recent months for clinical-stage medicines out of China-based drug developers. I spoke with Song about Candid, raising one of the year's largest private biotech financing rounds, the potential of T cell engagers in autoimmune and more for Endpoints News: #autoimmunediseases #autoimmunedrugs #tcellengagers #celltherapy #biotech #candidtherapeutics #venturecapital
Investors pour $370M+ into Ken Song's autoimmune biotech after his RayzeBio success
endpts.com